Can AI be trusted for clinical decisions in rheumatology? #ACR26 Abst 0869: Across 60 scenarios, guideline concordance reached 91.2% with OpenEvidence and 89.4% with ChatGPT. Hallucination rates: 3.8% and 6.2%. Promising tools, clinical oversight remains essential! @RheumNow https://t.co/mMdDULkw9U

X-sectional study from Brazil eval’d CAC prevalence across PREVENT categories Pop’n: Women w/ SLE 40-60yo and NO known ASCVD For SLE pts classified as Low risk in PREVENT, 21.9% were CAC+ suggesting subclinical ASCVD @RheumNow #ACR26 Abs0922 https://t.co/kMu6paK8Tv

Real-world claims data study showed ANI improved immunologic, renal & hematologic parameters in SLE pts Modest decr in UPCR (22%) Most significant improvement seen in leucopenia (overall 55%, IS-naive 80%) Improvement more prominent among IS-naive pts @RheumNow #ACR26 Abs0921 https://t.co/ax8QeA1syu

#ACR26 @RheumNow Ab#0478 Baricitinib in 84 RA-ILD pts Improved/stable dyspnea 83%, HRCT 68% at mean f/u 48 mos. DAS28-ESR from 4.3 to 2.8, median pred from 5 mg/d to 0 https://t.co/HTjUY7mHkV

SUNSTAR (n=224): first head-to-head trial of 2 non-TNFi bDMARDs. SC tocilizumab did not demonstrate superiority to abatacept on week-26 CDAI change. A secondary composite response favoured tocilizumab (51% vs 36%); more infections reported. #0468 #ACR26 @Rheumnow https://t.co/TbRvR2qUZf

#ACR26 @RheumNow Ab#0495 Leflunomide Duration and Dose - NOT associated with incident/progressive ILD Longitudinal study of 184 RA patients LEF associated with 4% lower risk of radiologic worsening, each gram of cumulative dose with 6.4% lower risk https://t.co/VeREpEQ5wc

Which SIJ lesions drive an “MRI indicative of axSpA”? -In SPARTAN CLASSIC (n=501, North America, <45y, undiagnosed back pain), erosion contributed most and was the only single lesion to hit ≥70% sens/≥90% spec. -Fat lesion, backfill and ankylosis were highly specific but lacked https://t.co/olq564FhSz

#ACR26 @RheumNow Ab#0448 Addition of Nintedanib to Abatacept in RA-ILD 80 pts progressive ILD, 263 non-progressive. NNTE added to 6 prog, 13 non-prog Non-prog- no signif results In prog RA-ILD, ABA+NINTE showed stabilized FVC on f/u over 48 mo https://t.co/MPpzqT4ajr

New IL-17 inhibitor on the block? Post-hoc analysis of Izokibep (small, selective IL-17A inhibitor) shows significant improvement over placebo in high-threshold outcomes including ACR70 response by week 16 #Abst0360 @RheumNow #ACR26 https://t.co/5tXgxBXK3C

Obesity & biologic response in RA: good EULAR response at 6m was 49.4% with obesity vs 61.1% without. A 5-lipid signature tracked non-response in obesity group. A possible metabolic link between obesity and treatment response. Requires further validation. @Rheumnow #0099 #ACR26 https://t.co/8cz9jPY9hJ